ON
OND.F Oncopeptides AB (publ)
- Market cap
- EUR 67.1M
- P/E
- -
- P/B
- 29.92x
- ROE
- -697.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is OND.F undervalued?
Graham numberThe Graham number of Oncopeptides AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oncopeptides AB (publ) fundamental analysis
No fundamental analysis for Oncopeptides AB (publ) yet.
Oncopeptides AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oncopeptides AB (publ)
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic…
Full company profileOncopeptides AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oncopeptides AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 19.4M | 118M | 8.36M | 35.2M | 31.6M | 71.1M | 113M |
| Gross Profit | - | 0.00 | 0.00 | 0.00 | 19.0M | 65.2M | 8.35M | 36.3M | 29.0M | 68.7M | 110M |
| Operating Income | -114M | -248M | -419M | -739M | -1.59B | -1.42B | -349M | -255M | -284M | -226M | -172M |
| EBITDA | - | -247M | -419M | -735M | -1.58B | -1.41B | -320M | -232M | -262M | -224M | -172M |
| Net Income | -114M | -248M | -419M | -741M | -1.59B | -1.43B | -338M | -249M | -285M | -250M | -174M |
| EPS | - | -6.22 | -9.51 | -13 | -23 | -19 | -3.58 | -1.96 | -1.35 | -0.91 | -0.46 |
| Balance Sheet | |||||||||||
| Total Assets | 55.6M | 480M | 445M | 993M | 947M | 439M | 385M | 238M | 244M | 135M | 222M |
| Total Liabilities | 29.3M | 61.8M | 129M | 196M | 370M | 229M | 91.0M | 182M | 190M | 194M | 197M |
| Shareholders' Equity | 26.3M | 418M | 316M | 797M | 577M | 211M | 294M | 56.8M | 54.3M | -58.9M | 24.9M |
| Cash & Short-term Investments | 40.3M | 404M | 376M | 926M | 840M | 362M | 345M | 173M | 179M | 82.3M | 158M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -104M | -271M | -334M | -691M | -1.30B | -1.52B | -421M | -279M | -261M | -223M | -177M |
| Capital Expenditure | 1.12M | 1.47M | 369K | 517K | 17.2M | 339K | 2.51M | 116K | 357K | 0.00 | 0.00 |
| Free Cash Flow | - | -273M | -334M | -693M | -1.31B | -1.52B | -423M | -280M | -261M | -223M | -177M |
| Ratios | |||||||||||
| ROE | -434.5% | -59.2% | -132.8% | -92.9% | -276.4% | -678.3% | -114.8% | -438.7% | -524.3% | - | -697.2% |
| ROA | -205.7% | -51.6% | -94.4% | -74.6% | -168.4% | -325.5% | -87.7% | -104.5% | -116.6% | -185.1% | -78.3% |
| Net Profit Margin | - | - | - | - | -8,239.2% | -1,209.1% | -4,044.9% | -707.3% | -899.3% | -350.9% | -153.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Oncopeptides AB (publ) dividends
Oncopeptides AB (publ) has not paid dividends in the last 9 fiscal years.
Who owns Oncopeptides AB (publ)
- Insiders 3.40%
- Institutions 12.98%
- Public & others 83.62%
- Shares outstanding 431M
- Free float 352M
Oncopeptides AB (publ) company profile
- Company name
- Oncopeptides AB (publ)
- Ticker
- OND.F
- ISIN
- SE0009414576
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Fiscal year end
- December
- Address
- Luntmakargatan 46, Stockholm, Sweden, 111 37
- Phone
- 46 86 15 20 40
- Website
- oncopeptides.com/sv
About Oncopeptides AB (publ)
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Oncopeptides AB (publ) management
10- Ms. Sofia Heigis M.Sc.Chief Executive Officer · born 1980
- Prof. Rolf Larsson M.D., Ph.D.Founder
- Prof. Rolf Lewensohn M.D., Ph.D.Founder
- Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D.Founder
- Dr. Kristina Luthman Ph.D.Founder
- Prof. Hans Ehrsson M.D.Founder
- Mr. Peter NygrenFounder · born 1959
- Mr. Henrik BergentoftChief Financial Officer · born 1974
- Ms. Eva Nordström M.Sc., MSc PharmCOO & Deputy MD · born 1970
- Mr. David AugustssonDirector of IR, Communications & Corporate Affairs · born 1984